Anticancer Drug Development, Breakthroughs are Waiting

Authors

  • Lu DY* School of Life Sciences, Shanghai University, Shanghai, China Author
  • Lu TR School of Life Sciences, Shanghai University, Shanghai, China Author
  • Yarla NR Divisions of Biochemistry & Chemistry, City University of New York School of Medicine, USA Author
  • Xu B Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China Author
  • Chen EH Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China Author
  • Ding J Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China Author

DOI:

https://doi.org/10.23880/apct-16000119

Keywords:

Anticancer drug development, Neoplasm metastasis, Cost-effective, Medicinal chemistry, Animal models, Drug toxicity, Cancer stem cells, Individualized cancer therapy

Abstract

New anticancer drug discovery, development and manufacture are entering into bottleneck stage at this moment. Many obstacles of biomedical, pharmaceutical, technology and economics lead to staggering pace of anticancer drug developments more recently. A declining successful rate of phase II and phase III anticancer drug evaluations is losing a great sum of money as well as human resource potentiality throughout the world. This editorial addresses some key factors affecting anticancer drug developments and providing possible avenues for drug development breakthroughs.

Downloads

Published

2017-12-01

Issue

Vol. 2 No. 1 (2017)

Section

Articles

License

Copyright (c) 2017 Lu DY

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

How to Cite

Anticancer Drug Development, Breakthroughs are Waiting. (2017). Advances in Pharmacology & Clinical Trials, 2(1), 1-4. https://doi.org/10.23880/apct-16000119

Most read articles by the same author(s)